{"id":5552,"date":"2015-05-08T10:12:48","date_gmt":"2015-05-08T10:12:48","guid":{"rendered":"\/?p=5552"},"modified":"2015-05-08T10:34:01","modified_gmt":"2015-05-08T10:34:01","slug":"pharmacyte-biotech-inc-otcmktspmcb-catches-a-break","status":"publish","type":"post","link":"\/articles\/pharmacyte-biotech-inc-otcmktspmcb-catches-a-break\/","title":{"rendered":"PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Catches a Break"},"content":{"rendered":"\n

Yesterday PharmaCyte Biotech, Inc. (OTCMKTS:PMCB<\/a>) managed to log a sizable reversal session, after a predominantly red streak. The ticker shifted nearly 4.3 million shares and closed over 7% up, at $0.16 per share.<\/p>\n

The company dropped a press release yesterday and it was most likely the reason for the green move. PMCB<\/a> opened with a very sizable gap up right out of the gates and the release hit the wire shortly before the opening bell. The company announced that the first round of pre-clinical animal safety testing using Melligen cells has been completed.<\/p>\n

The PR states that testing showed that Melligen cells were as safe as cells encapsulated with PMCB<\/a>‘s Cell-in-a-Box, combined with cancer drugs to treat human patients in previous human trials. This is a positive development and it’s understandable why the price went north. The direction the company is pushing in is eventual encapsulation of Melligen using Cell-in-a-Box, with the final goal of using this combo to help insulin-dependent diabetes patients live without daily insulin shots.<\/p>\n

Given the speed at which PMCB<\/a> goes through cash, the company will need sizable new financing to make it through 2015. The last quarterly listed just under $1 million in cash and $1.45 million in quarterly net loss.<\/p>\n

On the stock promotion front, it has been a quiet week for PMCB<\/a>. The last email pump for the company came on April 29 and the promoter was compensated with $7,500. There have been more than a hundred pump emails targeting PMCB<\/a> in 2015 so far – something that investors may want to keep in mind. Additionally, there was also Goldman Small Cap Research and the paid coverage they provided for PMCB<\/a>, last disclosing $11,000 paid by an unnamed third party.<\/p>\n","protected":false},"excerpt":{"rendered":"

Yesterday PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) managed to log a sizable reversal session, after a predominantly red streak. The ticker shifted nearly 4.3 million shares and closed over 7% up, at $0.16 per share. The...<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1635],"class_list":["post-5552","post","type-post","status-publish","format-standard","hentry","category-news","tag-pmcb"],"_links":{"self":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/5552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/comments?post=5552"}],"version-history":[{"count":0,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/5552\/revisions"}],"wp:attachment":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/media?parent=5552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/categories?post=5552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/tags?post=5552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}